BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 24656094)

  • 1. Aldoketoreductase family 1B10 (AKR1B10) as a biomarker to distinguish hepatocellular carcinoma from benign liver lesions.
    Matkowskyj KA; Bai H; Liao J; Zhang W; Li H; Rao S; Omary R; Yang GY
    Hum Pathol; 2014 Apr; 45(4):834-43. PubMed ID: 24656094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma.
    Chung YT; Matkowskyj KA; Li H; Bai H; Zhang W; Tsao MS; Liao J; Yang GY
    Mod Pathol; 2012 May; 25(5):758-66. PubMed ID: 22222635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Significance of 14-3-3ε, Aldo-keto Reductase Family 1 B10 and Metallothionein-1 in Hepatocellular Carcinoma.
    Wu CY; Jan YJ; Ko BS; Wu YJ; Wu YJ; Liou JY
    Anticancer Res; 2018 Dec; 38(12):6855-6863. PubMed ID: 30504401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High expression of aldo-keto reductase 1B10 is an independent predictor of favorable prognosis in patients with hepatocellular carcinoma.
    Ha SY; Song DH; Lee JJ; Lee HW; Cho SY; Park CK
    Gut Liver; 2014 Nov; 8(6):648-54. PubMed ID: 25287169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldo-Keto Reductases as Early Biomarkers of Hepatocellular Carcinoma: A Comparison Between Animal Models and Human HCC.
    Torres-Mena JE; Salazar-Villegas KN; Sánchez-Rodríguez R; López-Gabiño B; Del Pozo-Yauner L; Arellanes-Robledo J; Villa-Treviño S; Gutiérrez-Nava MA; Pérez-Carreón JI
    Dig Dis Sci; 2018 Apr; 63(4):934-944. PubMed ID: 29383608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Up-regulated aldo-keto reductase family 1 member B10 in chronic hepatitis C: association with serum alpha-fetoprotein and hepatocellular carcinoma.
    Sato S; Genda T; Hirano K; Tsuzura H; Narita Y; Kanemitsu Y; Kikuchi T; Iijima K; Wada R; Ichida T
    Liver Int; 2012 Oct; 32(9):1382-90. PubMed ID: 22681639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Knockdown or inhibition of aldo-keto reductase 1B10 inhibits pancreatic carcinoma growth via modulating Kras-E-cadherin pathway.
    Zhang W; Li H; Yang Y; Liao J; Yang GY
    Cancer Lett; 2014 Dec; 355(2):273-80. PubMed ID: 25304374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor induces tumour marker AKR1B10 expression through activator protein-1 signalling in hepatocellular carcinoma cells.
    Liu Z; Yan R; Al-Salman A; Shen Y; Bu Y; Ma J; Luo DX; Huang C; Jiang Y; Wilber A; Mo YY; Huang MC; Zhao Y; Cao D
    Biochem J; 2012 Mar; 442(2):273-82. PubMed ID: 22329800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of aldo-keto reductase family 1 member b10 in the early stages of human hepatocarcinogenesis.
    Tsuzura H; Genda T; Sato S; Murata A; Kanemitsu Y; Narita Y; Ishikawa S; Kikuchi T; Mori M; Hirano K; Iijima K; Wada R; Ichida T
    Int J Mol Sci; 2014 Apr; 15(4):6556-68. PubMed ID: 24747592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AKR1B10 expression is associated with less aggressive hepatocellular carcinoma: a clinicopathological study of 168 cases.
    Schmitz KJ; Sotiropoulos GC; Baba HA; Schmid KW; Müller D; Paul A; Auer T; Gamerith G; Loeffler-Ragg J
    Liver Int; 2011 Jul; 31(6):810-6. PubMed ID: 21645211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SUOX is a promising diagnostic and prognostic biomarker for hepatocellular carcinoma.
    Jin GZ; Yu WL; Dong H; Zhou WP; Gu YJ; Yu H; Yu H; Lu XY; Xian ZH; Liu YK; Cong WM; Wu MC
    J Hepatol; 2013 Sep; 59(3):510-7. PubMed ID: 23665285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemistry Detects Increased Expression of Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) in Early-Stage Hepatocellular Carcinoma.
    Han C; Gao L; Zhao L; Sheng Q; Zhang C; An Z; Xia T; Ding Y; Wang J; Bai H; Dou X
    Med Sci Monit; 2018 Oct; 24():7414-7423. PubMed ID: 30328412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum AKR1B10 as an indicator of unfavorable survival of hepatocellular carcinoma.
    Xie C; Ye X; Zeng L; Zeng X; Cao D
    J Gastroenterol; 2023 Oct; 58(10):1030-1042. PubMed ID: 37500927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of aldo-keto reductase family 1 member B10 on the risk of hepatitis C virus-related hepatocellular carcinoma.
    Sato S; Genda T; Ichida T; Murata A; Tsuzura H; Narita Y; Kanemitsu Y; Ishikawa S; Kikuchi T; Mori M; Hirano K; Iijima K; Wada R; Nagahara A; Watanabe S
    J Gastroenterol Hepatol; 2016 Jul; 31(7):1315-22. PubMed ID: 26758591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of AKR1B10 in nasopharyngeal carcinoma as a potential biomarker.
    He YC; Shen Y; Cao Y; Tang FQ; Tian DF; Huang CF; Tao H; Zhou FL; Zhang B; Song L; He L; Lin LM; Lu FG; Liao DF; Cao D
    Cancer Biomark; 2016; 16(1):127-35. PubMed ID: 26835713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Large-Scale Multicenter Study Validates Aldo-Keto Reductase Family 1 Member B10 as a Prevalent Serum Marker for Detection of Hepatocellular Carcinoma.
    Ye X; Li C; Zu X; Lin M; Liu Q; Liu J; Xu G; Chen Z; Xu Y; Liu L; Luo D; Cao Z; Shi G; Feng Z; Deng H; Liao Q; Cai C; Liao DF; Wang J; Jin J; Cao D
    Hepatology; 2019 Jun; 69(6):2489-2501. PubMed ID: 30672601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment AKR1B10 expression predicts the risk of hepatocellular carcinoma development after hepatitis C virus eradication.
    Murata A; Genda T; Ichida T; Amano N; Sato S; Tsuzura H; Sato S; Narita Y; Kanemitsu Y; Shimada Y; Hirano K; Iijima K; Wada R; Nagahara A; Watanabe S
    World J Gastroenterol; 2016 Sep; 22(33):7569-78. PubMed ID: 27672277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of aldo-keto-reductase family 1 B10 by 14-3-3ε and their prognostic impact of hepatocellular carcinoma.
    Liu TA; Jan YJ; Ko BS; Wu YJ; Lu YJ; Liang SM; Liu CC; Chen SC; Wang J; Shyue SK; Liou JY
    Oncotarget; 2015 Nov; 6(36):38967-82. PubMed ID: 26516929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical value of AKR1B10 in hepatocellular carcinoma: A systematic review and meta-analysis.
    Wang Z; Pei Y; Li W; Zhang J; Liu J
    PLoS One; 2022; 17(12):e0279591. PubMed ID: 36584078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions.
    Wang HL; Anatelli F; Zhai QJ; Adley B; Chuang ST; Yang XJ
    Arch Pathol Lab Med; 2008 Nov; 132(11):1723-8. PubMed ID: 18976006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.